Tissue	Disease	Species	symbol	ID	Platform	Type	Expression	Target	Pathway	Method	Drug	Function	PMID	Title	Year
liver	liver_cirrhosis	mus_musculus	TIMP1	7076	Gene	siRNA	down-regulation	NA	NA	qRT-PCR;  etc.	yes	Elevated tissue inhibitor of metalloproteinase 1 (timp-1) expression contributes to excess production of extracellular matrix in liver fibrosis.	23474083	Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis	2013
liver	liver_cirrhosis	mus_musculus	GALNAC	NA	NA	siRNA	dysregulation	GALNAC-SIRNA	NA	pharmacokinetic analysis; immunoblotting etc.	no	"Our data support a broad application of the galnac-sirna technology for hepatic targeting, including disease states where asgpr expression may be reduced."	28988716	Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression	2018
liver	liver_cirrhosis	mus_musculus	CD98hc	40941	Gene	siRNA	down-regulation	CD98 SIRNA	NA	 enzyme-linked immunosorbent assay; flow cytometry etc.	no	"Our results indicate that cd98 appears to function as a key actor;Inducer in nafld, and that our nps approach may offer a new targeted therapeutic for this disease."	27939923	CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice	2017
liver	liver_cirrhosis	mus_musculus	Foxf1	ENSMUSG00000042812?	Ensembl	siRNA	dysregulation	FOXF 1 SIRNA	NA	qRT-PCR etc.	yes	The present study was designed to confirm the therapeutic potential of foxf1 sirna in models of acute and chronic ccl4-induced liver injury. Dbtc-foxf1 sirna was only sufficient to silence foxf1 in acute ccl4model and did not ameliorate liver injury or fibrogenesis.	28629226	No significant impact of Foxf1 siRNA treatment in acute and chronic CCl 4 liver injury	2017